Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 15, Issue 2, Pages 92-111
Publisher
Springer Nature
Online
2017-11-14
DOI
10.1038/nrurol.2017.179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma
- (2017) Liqin Wang et al. EUROPEAN UROLOGY
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
- (2017) Marko Babjuk et al. EUROPEAN UROLOGY
- Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
- (2017) Sumati Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC).
- (2017) Gary D. Steinberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer
- (2017) Hui Yu et al. Journal of Thoracic Oncology
- Evolving adoptive cellular therapies in urological malignancies
- (2017) Yien Ning Sophia Wong et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
- (2017) Heather Katz et al. MEDICAL ONCOLOGY
- Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
- (2017) Jharna Datta et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
- (2017) Lian Dee Ler et al. Science Translational Medicine
- Targeted therapies in the treatment of urothelial cancers
- (2017) Jeanny B. Aragon-Ching et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Assays for PD-L1 Expression
- (2017) Gabriel L. Sica et al. JAMA Oncology
- A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs
- (2017) Derrick S. Haslem et al. Journal of Oncology Practice
- Branched evolution and intratumor heterogeneity of urothelial carcinoma of the bladder.
- (2017) Eugene K. Cha et al. JOURNAL OF CLINICAL ONCOLOGY
- Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
- (2017) Bernhard Kiss et al. Scientific Reports
- Tumor heterogeneity offibroblast growth factor receptor 3(FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
- (2016) D. Pouessel et al. ANNALS OF ONCOLOGY
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- Atezolizumab: First Global Approval
- (2016) Anthony Markham DRUGS
- Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
- (2016) Fiona S Togneri et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy
- (2016) Floris H. Groenendijk et al. EUROPEAN UROLOGY
- Prospect and progress of personalized peptide vaccinations for advanced cancers
- (2016) Shinjiro Sakamoto et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer
- (2016) Aryeh Keehn et al. Future Oncology
- The present status and future prospects of peptide-based cancer vaccines
- (2016) Masatoshi Hirayama et al. INTERNATIONAL IMMUNOLOGY
- Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress
- (2016) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.
- (2016) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
- (2016) Noura J. Choudhury et al. JOURNAL OF CLINICAL ONCOLOGY
- Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2016) Matthew I. Milowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select
- (2016) Charles G. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
- (2016) Peter E. Clark et al. Journal of the National Comprehensive Cancer Network
- A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform
- (2016) Tzahi Neuman et al. Journal of Thoracic Oncology
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
- (2016) Sam S. Chang et al. JOURNAL OF UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Bladder cancer
- (2016) Ashish M Kamat et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Perspective: The precision-oncology illusion
- (2016) Vinay Prasad NATURE
- Genentech's PD-L1 agent approved for bladder cancer
- (2016) Mark Ratner NATURE BIOTECHNOLOGY
- Clonal evolution of chemotherapy-resistant urothelial carcinoma
- (2016) Bishoy M Faltas et al. NATURE GENETICS
- What have we learned from SHIVA?
- (2016) Christophe Le Tourneau et al. Nature Reviews Clinical Oncology
- Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
- (2016) Malte Mohme et al. Nature Reviews Clinical Oncology
- Computational genomics tools for dissecting tumour–immune cell interactions
- (2016) Hubert Hackl et al. NATURE REVIEWS GENETICS
- Atezolizumab effective against advanced-stage disease
- (2016) Peter Sidaway Nature Reviews Urology
- Adaptive Randomization of Neratinib in Early Breast Cancer
- (2016) John W. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis
- (2016) George Papafotiou et al. Nature Communications
- Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
- (2016) Philipp H. Baldia et al. Oncotarget
- Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer
- (2016) Jessica Nakhlé et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma
- (2016) David Liu et al. JAMA Oncology
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
- (2016) Joshua I. Warrick et al. Scientific Reports
- Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma
- (2015) Sadakatsu Ikeda et al. CANCER TREATMENT REVIEWS
- An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
- (2015) M. Noguchi et al. CLINICAL CANCER RESEARCH
- Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma
- (2015) Metin Kurtoglu et al. Clinical Genitourinary Cancer
- Emerging concepts on drug resistance in bladder cancer: Implications for future strategies
- (2015) Francesco Massari et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapies for bladder cancer
- (2015) Farhad Fakhrejahani et al. CURRENT OPINION IN UROLOGY
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
- (2015) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder
- (2015) Philip H. Kim et al. EUROPEAN UROLOGY
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
- (2015) Elizabeth R. Plimack et al. EUROPEAN UROLOGY
- Bladder Preservation Strategies
- (2015) Ashesh B. Jani et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Nonurothelial Bladder Cancer and Rare Variant Histologies
- (2015) Daniel Willis et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer
- (2015) David J. McConkey et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Precision medicine: lessons learned from the SHIVA trial – Authors' reply
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Precision medicine: lessons learned from the SHIVA trial
- (2015) Apostolia M Tsimberidou et al. LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
- (2015) Cora N Sternberg et al. LANCET ONCOLOGY
- Characteristics of Exceptional or Super Responders to Cancer Drugs
- (2015) Vinay Prasad et al. MAYO CLINIC PROCEEDINGS
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- (2015) Ashish M. Kamat et al. Nature Reviews Urology
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics
- (2015) Stefan Vallo et al. Translational Oncology
- Targeted Therapy in Advanced Bladder Cancer
- (2015) Emmet J. Jordan et al. UROLOGIC CLINICS OF NORTH AMERICA
- BCG-refractory vs. BCG-relapsing non–muscle-invasive bladder cancer: A prospective cohort outcomes study
- (2015) Harry W. Herr et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- In Search of Exceptional Responders
- (2015) Cancer Discovery
- HER2 as a target in invasive urothelial carcinoma
- (2015) Joaquim Bellmunt et al. Cancer Medicine
- Training in ureteroscopy: a critical appraisal of the literature
- (2015) Ed Matsumoto BJU INTERNATIONAL
- Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
- (2015) Rodrigo Dienstmann et al. CANCER RESEARCH
- Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
- (2015) Lecia V. Sequist et al. CANCER RESEARCH
- Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents
- (2015) Steven C. Smith et al. NEOPLASIA
- Significance of MUC1 in bladder cancer
- (2014) Sarfraz Ahmad et al. BJU INTERNATIONAL
- Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
- (2014) Katherine C. Helming et al. CANCER CELL
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
- (2014) Katherine A. Hoadley et al. CELL
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Personalized Peptide Vaccine for Treatment of Advanced Cancer
- (2014) Tetsuro Sasada et al. CURRENT MEDICINAL CHEMISTRY
- New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician
- (2014) David J. McConkey et al. EUROPEAN UROLOGY
- The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease
- (2014) Robert S. Svatek et al. EUROPEAN UROLOGY
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- The mechanism of action of BCG therapy for bladder cancer—a current perspective
- (2014) Gil Redelman-Sidi et al. Nature Reviews Urology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
- (2014) E. M. Van Allen et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- Phase II study of everolimus in metastatic urothelial cancer
- (2013) Matthew I. Milowsky et al. BJU INTERNATIONAL
- Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells
- (2013) G. Redelman-Sidi et al. CANCER RESEARCH
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
- (2013) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
- (2013) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
- (2013) M. T. Herrera-Abreu et al. Cancer Discovery
- Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
- (2012) L Dyrskjøt et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- A Molecular Taxonomy for Urothelial Carcinoma
- (2012) G. Sjodahl et al. CLINICAL CANCER RESEARCH
- Oncogenic FGFR3 gene fusions in bladder cancer
- (2012) Sarah V. Williams et al. HUMAN MOLECULAR GENETICS
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Three differentiation states risk-stratify bladder cancer into distinct subtypes
- (2012) J.-P. Volkmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
- (2011) Meghan L. Rudd et al. CLINICAL CANCER RESEARCH
- Dynamic Mobility of Immunological Cells Expressing S100A8 and S100A9 in vivo: A Variety of Functional Roles of the two Proteins as Regulators in Acute Inflammatory Reaction
- (2011) Akiko Koike et al. INFLAMMATION
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- (2011) JOURNAL OF CLINICAL ONCOLOGY
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
- (2011) Yaoting Gui et al. NATURE GENETICS
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer
- (2010) Ganesh V. Raj et al. CANCER
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
- (2010) Tetsuro Sasada et al. EUROPEAN JOURNAL OF CANCER
- Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer
- (2010) Kenneth G. Nepple et al. JOURNAL OF UROLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer
- (2009) Per-Uno Malmström et al. EUROPEAN UROLOGY
- Genetic Susceptibility to Distinct Bladder Cancer Subphenotypes
- (2009) Lin T. Guey et al. EUROPEAN UROLOGY
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
- Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG
- (2009) LaMont J. Barlow et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Regulatory T Cells and Immune Tolerance
- (2008) Shimon Sakaguchi et al. CELL
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started